1997
DOI: 10.1021/js970079e
|View full text |Cite
|
Sign up to set email alerts
|

Evaluating a Possible Pharmacokinetic Interaction between Remifentanil and Esmolol in the Rat

Abstract: Remifentanil (Ultiva) is a novel, ultra-short-acting opioid which has recently been approved for use as an analgesic during induction and maintenance of general anesthesia. Esmolol is a short-acting beta-blocker used during surgical procedures to reduce heart rate and blood pressure. Both drugs are metabolized by nonspecific esterases in the blood and other tissues and may be administered concomitantly during surgery. The goal of this study was to determine if coadministration of esmolol significantly alters t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
21
1
1

Year Published

2000
2000
2014
2014

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(25 citation statements)
references
References 31 publications
2
21
1
1
Order By: Relevance
“…To that end, we investigated the involvement of AcbC ACh activation during the conditioning to the physiologicalreinforcer food (ie sweetened condensed milk) and compared it to AcbC ACh activation by morphine (MOR), a prototypical drug of abuse that belongs to the same pharmacological class as RMF, a m-opioid receptor agonist, but is pharmacokinetically very different from RMF. MOR elimination from rat plasma is biphasic with an initial t 1/2 of 21 min (90% of total MOR; our own recalculation of the data obtained by Bhargava et al (1993a, b, c) and a terminal t 1/2 of 222 min (Bhargava et al, 1993b), whereas RMF's (monophasic) elimination half-life in rat blood/plasma ranges from 0.3 min (single dose; Crespo et al, 2005) to 0.69-0.75 min (postinfusion; Cox et al, 1999;Haidar et al, 1997). Unfortunately, comparative MOR-vs-RMF data on the distribution into brain areas are not available at a satisfactory temporal resolution.…”
Section: Introductionmentioning
confidence: 62%
“…To that end, we investigated the involvement of AcbC ACh activation during the conditioning to the physiologicalreinforcer food (ie sweetened condensed milk) and compared it to AcbC ACh activation by morphine (MOR), a prototypical drug of abuse that belongs to the same pharmacological class as RMF, a m-opioid receptor agonist, but is pharmacokinetically very different from RMF. MOR elimination from rat plasma is biphasic with an initial t 1/2 of 21 min (90% of total MOR; our own recalculation of the data obtained by Bhargava et al (1993a, b, c) and a terminal t 1/2 of 222 min (Bhargava et al, 1993b), whereas RMF's (monophasic) elimination half-life in rat blood/plasma ranges from 0.3 min (single dose; Crespo et al, 2005) to 0.69-0.75 min (postinfusion; Cox et al, 1999;Haidar et al, 1997). Unfortunately, comparative MOR-vs-RMF data on the distribution into brain areas are not available at a satisfactory temporal resolution.…”
Section: Introductionmentioning
confidence: 62%
“…Pharmacokinetic models generally describe plasma drug concentration with a bi-exponential decay accounting for redistribution of drug to a generalized peripheral compartment, plus systemic elimination of drug. However, measured blood concentrations of remifentanil in the rat exhibit rapid, single exponential decay (Haidar et al, 1997).…”
Section: Discussionmentioning
confidence: 98%
“…The white cue light at the end of the runway was also illuminated during the noncontingent condition. Intertrial intervals of 40 min (RMF) or 60 min (COC) were chosen to guarantee de facto elimination of the drug from the brain (Pan et al, 1991;Haidar et al, 1997;Hemby et al, 1997;Cox et al, 1999) before the start of the next trial. The operant level was determined with intravenous saline in another six rats, using a run-time cutoff of 60 s. Runway dimensions and experimental details have been published previously (Wakonigg et al, 2003a(Wakonigg et al, ,b, 2004.…”
Section: Methodsmentioning
confidence: 99%